ReviewBrain tumor pathology2022
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Review in Brain tumor pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Treatment-induced ripple effect: a systematic review exploring the abscopal phenomenon in Glioblastoma multiforme.Journal of neuro-oncology · 2025Pooled it
- Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas.Cancer gene therapy · 2026Article
- Cracking the shield: oncolytic viruses versus the tumor-immune fortress.Cancer cell international · 2026Review
- Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).International journal of molecular medicine · 2025Review
- Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma.iScience · 2025Article
- An attenuated coxsackievirus B5 mutant carrying VP1-N157K retains oncolytic potency against non-small cell lung cancer.Molecular therapy. Oncology · 2025Article
- The Role of Viruses in the Glioma Tumor Microenvironment: Immunosuppressors or Primers for Anti-Tumor Immunity?Cancers · 2025Review
- Integrative bioinformatic and experimental analysis reveals prognostic and immunological roles of MEX3 family genes in glioma.Frontiers in immunology · 2025Article
- Cancer biotherapy: review and prospect.Clinical and experimental medicine · 2024Review
- Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.Brain tumor pathology · 2023Review
- HSV: The scout and assault for digestive system tumors.Frontiers in molecular biosciences · 2023Review
- Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects.Journal of clinical medicine · 2022Review
- Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.Viruses · 2022Article
- Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Despite current progress in treatment, glioblastoma (GBM) remains a lethal primary malignant tumor of the central nervous system. Although immunotherapy has recently achieved remarkable survival effectiveness in multiple malignancies, none of the immune checkpoint inhibitors (ICIs) for GBM have shown anti-tumor efficacy in clinical trials. GBM has a characteristic immunosuppressive tumor microenvironment (TME) that results in the failure of ICIs. Oncolytic herpes simplex virotherapy (oHSV) is the most advanced United States Food and Drug Administration-approved virotherapy for advanced metastatic melanoma patients. Recently, another oHSV, Delytact
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.